Sickle cell disease (SCD) is an inherited blood condition that affects an estimated 100,000 individuals in the United States, a disproportionate number of whom are Black and Hispanic Americans. While newborn screening for SCD occurs in every state, there are still barriers to accessing comprehensive, high-quality care throughout a person’s lifespan, and many individuals with SCD—notably people of color--encounter barriers to accessing evidence-based care, new medications and therapies, and other supports. The Health Resources and Services Administration’s (HRSA) Maternal and Child Health Bureau (MCHB), contracted with Abt Global and partner the National Institute for Children’s Health Quality (NICHQ) to strengthen the SCD system of care and support by managing its Hemoglobinopathies National Coordinating Center (HNCC). The HNCC’s objectives are to build a foundation based on local and regional partnerships through regional action plans—and focus on the implementation of successful strategies such as assembling comprehensive SCD care teams, supporting access to disease modifying therapies, and hub-and-spoke models in which specialty sickle cell centers provide support in the co-management of care with more local healthcare providers for SCD patients.